Sun Pharma Enters Licensing Pact With Lundbeck To Launch Novel Anti-Depressant Pill In India
Vortioxetine Is A Novel Antidepressant With Multimodal Activity, Which Is Approved To Treat Major Depressive Disorder (Mdd) In Adults. Sun Pharma On Wednesday Said It Has Entered Into An Exclusive Patent Licensing Agreement With Danish-Drugmaker Lundbeck To Market And Distribute Its Own Version Of Antidepressant Medication Vortioxetine In India Under The Brand Name Vortidiftm. The Territory Of The Licensing Agreement Will Only Cover India. Vortioxetine Is A Novel Antidepressant With Multimodal Activity, Which Is Approved To Treat Major Depressive Disorder (Mdd) In Adults. The Product Is Approved In Over 80 Countries, Including The Us, Eu, Canada And Australia.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
